A potential concern for assessing ER expression in ovarian cancer patients could be the location of the tumor in the abdominal area where visualization can be hampered by the high physiological background uptake of [18F]FES in the liver, gallbladder, intestines, ovaries, and bladder [20]. The gene discussed is ESR1; the disease is neoplasm.